Deepak L. Bhatt
Practice takeDirector, Mount Sinai Fuster Heart HospitalConsistent hs-CRP reductions across subgroups make a strong case for continued evaluation
Original post ↗View all ESC 2026 trials
TRANQUILITYPreventionOpen Access
Monthly and quarterly pacibekitug in patients with chronic kidney disease at high cardiovascular risk
What happened
Pacibekitug cuts hs-CRP by up to ~89% versus placebo in patients with CKD.
- P<0.0001
- n=143
Does this change practice?
Where experts agree
Multiple clinicians highlight that while TRANQUILITY demonstrates compelling target engagement, the ZEUS experience with ziltivekimab shows that deep IL-6 suppression and hs-CRP lowering may not translate into cardiovascular event reduction. Outcomes data remain the missing piece.
What this trial adds
Experts see TRANQUILITY's sustained hs-CRP reductions as impressive proof of IL-6 target engagement, but most stress that biomarker lowering alone does not guarantee cardiovascular benefit and that outcomes trials are essential.
Published field read
Clinicians agree pacibekitug powerfully suppressed inflammation in CKD patients, with the convenience of quarterly dosing drawing particular attention. However, the shadow of ZEUS, in which another IL-6 inhibitor lowered hs-CRP yet failed to reduce cardiovascular events, tempers enthusiasm considerably. The central open question is whether this degree of target engagement will translate into actual clinical benefit in a phase 3 outcomes trial.
Still open
Questions raised in published commentaryWhether pacibekitug's hs-CRP reductions will translate into reduced cardiovascular events remains the key unanswered question, especially given the negative ZEUS outcomes result with a different IL-6 inhibitor.
It is also unclear whether the effect's disappearance after treatment stops (noted by one clinician) limits its practical utility, and whether quarterly dosing offers a meaningful advantage over more frequent regimens in an outcomes setting.
Context from published commentary. Source summaries are not a new guideline recommendation.
Who says what
ZEUS showed another IL-6 inhibitor lowered hs-CRP in a similar population but produced no MACE benefit
X post ↗
Quarterly dosing achieved persistent hs-CRP reduction, but the effect disappeared when treatment stopped
X post ↗Show 5 more perspectivesShow fewer perspectives
Ahmed BennisResults readoutHeart Failure / Cardiomyopathy · Centre Hospitalier Universitaire Hassan II
Primary endpoint was hit with sustained hsCRP reductions across all active doses through day 180
X post ↗
Edgardo AlaniaResults readout
Compelling target engagement but not proof of CV benefit, and ZEUS is a warning
X post ↗
C. Michael GibsonResults readoutInterventional / Structural Cardiology · Beth Israel Deaconess Medical Center
Discussed the trial as showing significant hs-CRP reductions and favorable inflammatory and cardiometabolic biomarker changes without a safety signal.
X post ↗Sandeep Kulkarni
Results readoutCo-Founder and CEO, Tourmaline BioCalled the consistency of signal across all endpoints remarkable and highlighted that this is the first time any IL-6 inhibitor has been tested with quarterly dosing, which may enhance patient adherence.
Original post ↗Lane Hollrah 6
@6hollrah“TRANQUILITY and The Frequency Of Good And Every Healing Life Giving Things AND ACTIONABLE SOLUTIONS TO CHANGE THE WORLD AND ILL HAVE NO BIAS AND REGURGITATING OLD IDEAS WITHOUT LIFE OR THE BECOMING, Of Any Twisted Thing Or Thought Form Propagated In Self Defense”
X ↗What should the author answer first?
Upvote a question you would like answered, or open it to join the discussion.
Full evidence
Why the trial, key points, tables, limitations, PICO, abstract, media & sources
Full evidence
Why the trial, key points, tables, limitations, PICO, abstract, media & sources
Why the trial?
IL-6-driven inflammation contributes to cardiovascular risk in chronic kidney disease, but durable IL-6 blockade with infrequent dosing had not been established. TRANQUILITY tested whether monthly or quarterly pacibekitug sustainably lowers hs-CRP with acceptable safety in stage 3-4 CKD at high cardiovascular risk.
Does subcutaneous pacibekitug reduce hs-CRP in patients with stage 3-4 chronic kidney disease and elevated hs-CRP?
View moreView less
Key Points
- To evaluate the efficacy and safety of the long-acting interleukin-6 monoclonal antibody pacibekitug in reducing inflammatory markers in patients with stage 3–4 chronic kidney disease.
- Phase II randomized trial across 49 US centers enrolling 143 patients (mean age 69 years; 64% women) with stage 3–4 chronic kidney disease and elevated hs-CRP (2 to <15 mg/L).
- Participants were randomized 1:1:1:1 to subcutaneous pacibekitug (25 mg every 90 days, 50 mg every 90 days, or 15 mg every 30 days) or placebo for six months.
- Median time-averaged change in hs-CRP from baseline through day 180 was +7% with placebo compared to −76% with 25 mg every 90 days, −85% with 50 mg every 90 days, and −89% with 15 mg every 30 days (all p<0.0001 vs placebo).
- Pacibekitug also reduced fibrinogen and lipoprotein(a) levels and was well tolerated, with an overall discontinuation rate of 1.9% and no clear dose-related safety signals.
Evidence details
What drove the result?
| Outcome | Placebo | 25 mg q90d | 50 mg q90d | 15 mg q30d |
|---|---|---|---|---|
| hs-CRP, median time-averaged change to day 180 | +7% | -76% | -85% | -89% |
| Dose-dependent; all p<0.0001 vs placebo; sustained from day 30 | ||||
Limitations & tradeoffs
Safety
Treatment discontinuations 1.9% overall with no clear dose-related safety signals (per-arm counts not reported).
Design limitations
phase 2 trial with a biomarker (hs-CRP) endpoint, not clinical outcomes, and results come from the congress press release with no simultaneous publication.
Statistical certainty
only 143 patients across four arms.
Structured PICO
Does subcutaneous pacibekitug reduce hs-CRP in patients with stage 3-4 chronic kidney disease and elevated hs-CRP?
P
Population
143 patients (mean age 69, 64% women) with stage 3-4 chronic kidney disease and elevated hs-CRP, followed for six months.
I
Intervention
Subcutaneous pacibekitug 25 mg or 50 mg every 90 days, or 15 mg every 30 days for six months.
C
Comparator
Placebo for six months.
O
Outcome
Median time-averaged change from baseline in hs-CRP through day 180.surrogate
Main Result
Absolute Event Rate: -89% vs 7%
p-value: p=<0.0001
Limitations
- No simultaneous results paper was available at presentation; source is a press release
Discussion
No takes yet. Share an insight, caveat, or question.
Expert reaction
What experts said about TRANQUILITY
ESC Congress 2026
1 expert has reacted so far. We show the split once 3 have.
Expert labels are toward TRANQUILITY's result, from named public quotes (n=1). As of Aug 27, 2026.
Where experts stand
Experts see TRANQUILITY's sustained hs-CRP reductions as impressive proof of IL-6 target engagement, but most stress that biomarker lowering alone does not guarantee cardiovascular benefit and that outcomes trials are essential.
Clinicians agree pacibekitug powerfully suppressed inflammation in CKD patients, with the convenience of quarterly dosing drawing particular attention. However, the shadow of ZEUS, in which another IL-6 inhibitor lowered hs-CRP yet failed to reduce cardiovascular events, tempers enthusiasm considerably. The central open question is whether this degree of target engagement will translate into actual clinical benefit in a phase 3 outcomes trial.
Agreement
Multiple clinicians highlight that while TRANQUILITY demonstrates compelling target engagement, the ZEUS experience with ziltivekimab shows that deep IL-6 suppression and hs-CRP lowering may not translate into cardiovascular event reduction. Outcomes data remain the missing piece.
2 clinicians say this directly
What they’re arguing about
supportiveneutralcautiouscritical
Counts are expert takes we classified by axis. Tap a row to see the takes behind its count.
Still unclear
Whether pacibekitug's hs-CRP reductions will translate into reduced cardiovascular events remains the key unanswered question, especially given the negative ZEUS outcomes result with a different IL-6 inhibitor. It is also unclear whether the effect's disappearance after treatment stops (noted by one clinician) limits its practical utility, and whether quarterly dosing offers a meaningful advantage over more frequent regimens in an outcomes setting.
Key expert perspectives
DLDeepak L. BhattDirector, Mount Sinai Fuster Heart HospitalPractice takeBefore results
Consistent hs-CRP reductions across subgroups make a strong case for continued evaluation
States that pacibekitug demonstrated rapid, deep, and consistent hs-CRP reductions across subgroups including sex, body mass index, diabetes status, and baseline GLP-1 and GIP/GLP-1 receptor agonist use. Concludes the data make a strong case for continued evaluation in atherosclerotic cardiovascular disease and other inflammation-driven cardiovascular diseases, and that pacibekitug merits testing in phase 3 trials for cardiovascular risk reduction.
ZEUS showed another IL-6 inhibitor lowered hs-CRP in a similar population but produced no MACE benefit
Flags that ZEUS tested ziltivekimab in over 6,300 patients with ASCVD, CKD, and inflammation and found no MACE benefit despite clear IL-6 target engagement and substantial hs-CRP lowering. Frames this as critical context for interpreting TRANQUILITY.
Quarterly dosing achieved persistent hs-CRP reduction, but the effect disappeared when treatment stopped
Notes pacibekitug achieved significant and persistent hsCRP reduction within 180 days with no safety concerns, but highlights that the effect disappeared after day 180 when treatment was stopped.
Distilled from their postX post
Implication
The long-acting IL-6 inhibitor pacibekitug produced significant, dose-dependent reductions in hs-CRP among patients with stage 3-4 CKD and high cardiovascular risk.
Abstract
The phase II TRANQUILITY trial, presented at ESC Congress 2026, evaluated the long-acting IL-6 monoclonal antibody pacibekitug in 143 patients with stage 3–4 chronic kidney disease and elevated hs-CRP (2 to <15 mg/L) at 49 US centres. Participants were randomised 1:1:1:1 to subcutaneous pacibekitug 25 mg or 50 mg every 90 days, 15 mg every 30 days, or placebo for six months. Mean age was 69 years; 64% were women. Pacibekitug produced dose-dependent hs-CRP decreases by day 30 that were sustained to day 180. Median time-averaged change from baseline in hs-CRP through day 180 was +7% with placebo, −76% with 25 mg every 90 days, −85% with 50 mg every 90 days, and −89% with 15 mg every 30 days (all p<0.0001 vs placebo). Other inflammatory markers, fibrinogen, and lipoprotein(a) also fell. Pacibekitug was well tolerated (1.9% discontinuations) with no clear dose-related safety signals. No simultaneous results paper was available at presentation; source is the ESC Congress 2026 press release.
Coverage & sources
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Cite This Study
Deepak Bhatt (2026) conducted an RCT in Stage 3-4 chronic kidney disease and elevated hs-CRP (n=143). Pacibekitug vs. Placebo was evaluated on Median time-averaged change from baseline in hs-CRP through day 180 (p=<0.0001). Pacibekitug significantly reduced hs-CRP compared to placebo in patients with stage 3-4 chronic kidney disease, with median time-averaged changes up to -89% versus +7% (p<0.0001).